Gamal Mohamed

Dr. Gamal Mohamed

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
HAHend Almuhaya
Hend Almuhaya
RARaghad Alsalamah
Raghad Alsalamah
ASAsma Sallam
Asma Sallam
AAAmgad Alonazy
Amgad Alonazy
AAAtheer AlAwwad
Atheer AlAwwad
BABadr F Al-Bawardy
Badr F Al-Bawardy
Background: Inflammatory bowel disease (IBD) can lead to zinc deficiency, which plays a critical role in immune function and tissue repair. This study aims to determine the prevalence, clinical characteristics, and impact of zinc deficiency in IBD patients. Methods: This is a retrospective study of patients aged ≥14 years with confirmed IBD and available zinc level measurement. Zinc deficiency was defined as a level <10.6 µmol/L. Primary outcomes included the prevalence of zinc deficiency and the characterization of the clinical profile of patients with zinc deficiency. Secondary outcomes included IBD-related hospitalizations, emergency room visits, surgeries, and complications (anemia, small bowel obstruction, new perianal disease, intra-abdominal abscess). Results: Among 447 patients (54.4% male; 79.2% Crohn’s disease) with a median age of 29 years (IQR: 22–38), 45.6% had zinc deficiency (83.8% Crohn’s disease). Zinc-deficient patients had higher C-reactive protein and fecal calprotectin (both p < 0.001) levels, and were more likely to be on corticosteroids (p = 0.04). Zinc deficiency was associated with higher rates of IBD-related hospitalizations (48.0% vs. 17.7%), surgeries (19.6% vs. 5.8%), complications (30.4% vs. 12.4%), and emergency room visits (40.2% vs. 17.3%) (all p < 0.001). Upon multivariate analysis, predictors of IBD-related hospitalization were zinc deficiency (OR 2.42, 95% CI 1.07–5.48, p = 0.03) and low albumin (OR 9.03, 95% CI 3.38–24.15, p < 0.001). Zinc deficiency was associated with IBD-related surgeries (OR 5.23, 95% CI 1.27–21.45, p = 0.02) and complications (OR 3.98, 95% CI 1.52–10.41, p = 0.005). Conclusions: Zinc deficiency is prevalent in patients with IBD, associated with a high inflammatory burden, and was linked to worse clinical outcomes after controlling for markers of inflammation.

24 December 2024 in Endocrine Practice
Verified
Journal Article
Open access
ZDZainab Al Duhailib
Zainab Al Duhailib
HHHakeam Hakeam
Hakeam Hakeam
AAAmmar Almossalem
Ammar Almossalem
AAAhood Alrashidi
Ahood Alrashidi
AZAbdulrahman Al Zhrani
Abdulrahman Al Zhrani
BRBram Rochwerg
Bram Rochwerg
Dysglycemia has deleterious outcomes on critically ill patients with diabetes mellitus (DM). Insulin degludec, an ultra-long-acting insulin, is associated with lower rates of hypoglycemia and blood glucose (BG) variability in non-critically ill patients. The experience with insulin degludec in the intensive care units is lacking. This study aimed to assess the effect of insulin degludec on glycemic control in critically ill patients with type 2 DM. A prospective, interventional study enrolled critically ill patients with type 2 DM. Subjects were started on insulin degludec plus insulin regular correctional doses. BG levels were assessed every 6 hours. The primary outcome was the percentage of BG levels within a target of 140-180 mg/dL. Secondary outcomes included median BG levels, severe hypoglycemia rate, and BG variability. In total 155 patients were enrolled. The percentage of BG levels within the target was 28.4%. The first day that the median of BG levels within target was on day two of insulin degludec therapy and continued within the target for one week. Severe hypoglycemia developed in 5 (3.2%) patients. The BG variability in the study was 26% using the coefficient of variation. In critically ill patients with type 2 DM, one-fourth of BG levels were within the glycemic target (140-180 mg/dL) with insulin degludec plus insulin regular correctional doses. The median BG levels was in target starting the second day of insulin degludec therapy. The favorable BG variability using insulin degludec merits further investigation for effect on clinical outcomes.

4 December 2025 in Epileptic Disorders
Verified
Journal Article
Closed access
MAMohammed Saqer Alshammari
Mohammed Saqer Alshammari
HDHasan Mohammed Daghriri
Hasan Mohammed Daghriri
MAMuteb Mohammed Aldawsari
Muteb Mohammed Aldawsari
GMGamal Mohamed
Gamal Mohamed
AAAyman A. AbdelHamid
Ayman A. AbdelHamid
SDSasha Dionisio
Sasha Dionisio